Maastricht
Maastricht
Maastricht, Netherlands314 results · Page 1 of 13
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Registry Maastro Applicator | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal cancer, rectal disorder, rectal neoplasm | Recruiting | Not stated | 2026-10-09 | NCT07501845 | |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07284849 | |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-10-09 | NCT06878261 | |
| A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-10-09 | NCT06585774 | |
| Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP) | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fistula, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Vascular Fistula, arteriovenous hemangioma/malformation, cardiovascular disorder, congenital arteriovenous fistula, vascular disorder, vascular malformation | Active, not recruiting | Not stated | 2026-10-09 | NCT05062291 | |
| Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy | Head and Neck Neoplasms, Neoplasms by Site, head and neck cancer, neoplasm | Recruiting | Not stated | 2026-10-09 | NCT01985984 | |
| A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 3 | 2026-10-08 | NCT07522073 | |
| Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-10-08 | NCT07223814 | |
| The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | Chronic Disease, Death, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, heart disorder, heart failure, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT05374291 | |
| Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2026-10-08 | NCT05255653 | |
| TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2026-10-07 | NCT06931769 | |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-07 | NCT06890598 | |
| Vorasidenib Maintenance for IDH Mutant Astrocytoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-10-07 | NCT06809322 | |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-07 | NCT04910685 | |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07173751 | |
| Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT04663347 | |
| Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-10-06 | NCT04628026 | |
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT03625037 | |
| Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, Myotonia, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic dystrophy type 1, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular disease | Recruiting | Phase 3 | 2026-10-05 | NCT07486934 | |
| A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Symptomatic Genetic Dilated Cardiomyopathy | Recruiting | Phase 2 / Phase 3 | 2026-10-05 | NCT07210723 | |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-05 | NCT06982521 | |
| The Intensive Care Platform Trial | Critical Illness, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Recruiting | Phase 4 | 2026-10-05 | NCT06667999 | |
| Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm, non-Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2026-10-05 | NCT05641428 | |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, adenoma, carcinoid tumor, carcinoma, digestive system neuroendocrine neoplasm, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine neoplasm, pancreas disorder, pancreatic neoplasm, pancreatic neuroendocrine tumor, primitive neuroectodermal tumor | Active, not recruiting | Phase 3 | 2026-10-05 | NCT05477576 | |
| Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | Arterial Occlusive Diseases, Infarction, Inflammation, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, nervous system disorder, peripheral arterial disease, peripheral vascular disease, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2026-10-05 | NCT04774159 |